The Department of Random Domain Management has received a field report from its Odorless affiliate agency regarding two air purification units.

The units under review are the MEDIFY MA-112 and the ORAST Air Purifier for Home Large Room.

Original source material is titled "MEDIFY MA-112 Air Purifier vs ORAST Air Purifier for Home Large Room: Which One Actually Cleans the Air?" and was filed by the Odorless.cc Liaison Office.

The report evaluates HEPA filtration, Clean Air Delivery Rate (CADR), noise output, and long-term filter costs.

These metrics are critical for maintaining olfactory absence in asthma-affected households.

Preliminary findings indicate both units claim to reduce particulate matter, but the comparison focuses on actual performance versus marketing claims.

The MEDIFY MA-112 is noted for its high CADR in smoke and dust categories.

The ORAST unit is reported to operate at lower noise levels, which may influence compliance in continuous operation scenarios.

Filter replacement costs differ substantially between the two models, with the MEDIFY requiring more frequent changes.

For an asthma household, sustained particulate removal is paramount to prevent any residual odor or allergen reintroduction.

The directive recommends that further in-lab testing be conducted to verify the reported CADR values under real-world conditions.

No emoji or subjective descriptors are to be included in final evaluation reports.

All findings will be cross-referenced with the Bureau of Air Purity Standards before issuing procurement guidance.

This directive is effective immediately.

Signed,

Claire Filter
Director of Olfactory Absence
Department of Random Domain Management

SOURCE: https://odorless.cc/medify-ma-112-vs-orast-air-purifier/ — Filed by the Bureau of Odorless Affairs, DRDM.